Gerald L. Messerschmidt

751 total citations
26 papers, 559 citations indexed

About

Gerald L. Messerschmidt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Gerald L. Messerschmidt has authored 26 papers receiving a total of 559 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in Gerald L. Messerschmidt's work include Cancer Research and Treatments (4 papers), Virus-based gene therapy research (4 papers) and CAR-T cell therapy research (3 papers). Gerald L. Messerschmidt is often cited by papers focused on Cancer Research and Treatments (4 papers), Virus-based gene therapy research (4 papers) and CAR-T cell therapy research (3 papers). Gerald L. Messerschmidt collaborates with scholars based in United States, Malaysia and India. Gerald L. Messerschmidt's co-authors include George C. Prendergast, Robert C. Young, Albert Deisseroth, Robert F. Ozols, Nasser Javadpour, Audrey Barlock, Harry W. Snyder, Frank R. Jones, Joseph P. Balint and Juergen H. Bertram and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Gerald L. Messerschmidt

26 papers receiving 519 citations

Peers

Gerald L. Messerschmidt
C.R. Franks France
M. Brandely France
Hideo Goto Japan
J. L. Pico France
Yu Oyama Japan
S. N. Markovic United States
Hisako Inoue Japan
Paolo Fiumara Italy
Z Domljan Croatia
Pamela Bartels United States
C.R. Franks France
Gerald L. Messerschmidt
Citations per year, relative to Gerald L. Messerschmidt Gerald L. Messerschmidt (= 1×) peers C.R. Franks

Countries citing papers authored by Gerald L. Messerschmidt

Since Specialization
Citations

This map shows the geographic impact of Gerald L. Messerschmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald L. Messerschmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald L. Messerschmidt more than expected).

Fields of papers citing papers by Gerald L. Messerschmidt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald L. Messerschmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald L. Messerschmidt. The network helps show where Gerald L. Messerschmidt may publish in the future.

Co-authorship network of co-authors of Gerald L. Messerschmidt

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald L. Messerschmidt. A scholar is included among the top collaborators of Gerald L. Messerschmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald L. Messerschmidt. Gerald L. Messerschmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gyorffy, Steve, et al.. (2020). Efficiency: Minimizing dose escalation steps by calculating human dosing preclinically.. Journal of Clinical Oncology. 38(15_suppl). e15622–e15622. 1 indexed citations
2.
Bhattacharya, Prianka, et al.. (2017). Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics. Current Oncology Reports. 19(10). 66–66. 11 indexed citations
3.
4.
Balint, Joseph P., Elizabeth S. Gabitzsch, Adrian Rice, et al.. (2015). Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. Cancer Immunology Immunotherapy. 64(8). 977–987. 37 indexed citations
5.
6.
Robert, Francisco, Herbert I. Hurwitz, Hope E. Uronis, et al.. (2008). 283 POSTER Phase 1 trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients. European Journal of Cancer Supplements. 6(12). 91–92. 8 indexed citations
7.
Snyder, Harry W., A Mittelman, Ayhan Oral, et al.. (1993). Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer. 71(5). 1882–1892. 83 indexed citations
8.
Snyder, Harry W., Juergen H. Bertram, David H. Henry, et al.. (1991). Use of protein A immunoadsorption as a treatment for thrombocytopenia in HIV-infected homosexual men. AIDS. 5(10). 1257–1260. 17 indexed citations
9.
Snyder, Harry W., David H. Henry, Gerald L. Messerschmidt, et al.. (1991). Minimal toxicity during protein a immunoadsorption treatment of malignant disease: An outpatient therapy. Journal of Clinical Apheresis. 6(1). 1–10. 20 indexed citations
10.
Thompson, James, et al.. (1988). Recurrent hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in hodgkin's disease. The American Journal of Medicine. 84(1). 165–168. 23 indexed citations
11.
Leff, Richard, James Thompson, Mary B. Daly, et al.. (1988). Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer. 62(1). 32–35. 23 indexed citations
12.
Messerschmidt, Gerald L., Robert Makuch, F R Appelbaum, et al.. (1988). A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients. Cancer. 62(4). 795–801. 15 indexed citations
13.
Messerschmidt, Gerald L., David H. Henry, Harry W. Snyder, et al.. (1988). Protein A immunoadsorption in the treatment of malignant disease.. Journal of Clinical Oncology. 6(2). 203–212. 36 indexed citations
14.
Leff, Richard, David B. Johnson, Mary B. Daly, et al.. (1986). Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma.. Journal of Clinical Oncology. 4(11). 1586–1591. 32 indexed citations
15.
Ozols, Robert F., A B Deisseroth, Nasser Javadpour, et al.. (1984). Treatment of Poor Prognosis Nonseminomatous Testicular Cancer with a “High-Dose” Platinum Combination Chemotherapy Regimen. The Journal of Urology. 131(1). 181–181. 3 indexed citations
16.
Foss, Francine M., John G. Horneff, Dan L. Longo, & Gerald L. Messerschmidt. (1983). Cerebrospinal fluid rhinorrhea as a complication of malignant lymphoma. The American Journal of Medicine. 74(6). 1077–1079. 3 indexed citations
17.
Messerschmidt, Gerald L., et al.. (1983). Prognostic Indicators of Tumor Response to <italic>Staphylococcus aureus</italic> Cowan Strain I Plasma Perfusion<xref ref-type="fn" rid="FN2">2</xref>. JNCI Journal of the National Cancer Institute. 71(3). 535–8. 4 indexed citations
18.
Ozols, Robert F., Albert Deisseroth, Nasser Javadpour, et al.. (1983). Treatment of poor prognosis nonseminomatous testicular cancer with a “high-dose” platinum combination chemotherapy regimen. Cancer. 51(10). 1803–1807. 113 indexed citations
19.
Sharp, Thomas G., David H. Sachs, Anthony S. Fauci, Gerald L. Messerschmidt, & Steven A. Rosenberg. (1983). T CELL DEPLETION OF HUMAN BONE MARROW USING MONOCLONAL ANTIBODY AND COMPLEMENT-MEDIATED LYSIS. Transplantation. 35(2). 112–120. 10 indexed citations
20.
Messerschmidt, Gerald L., M. T. Parker, R Lester, et al.. (1982). Phase I trial of Staphylococcus aureus Cowan I immunoperfusion.. PubMed. 66(12). 2027–31. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C.R. Franks Breakdown of academic impact, for papers by M. Brandely Breakdown of academic impact, for papers by Hideo Goto Breakdown of academic impact, for papers by J. L. Pico Breakdown of academic impact, for papers by Yu Oyama Breakdown of academic impact, for papers by S. N. Markovic Breakdown of academic impact, for papers by Hisako Inoue Breakdown of academic impact, for papers by Paolo Fiumara Breakdown of academic impact, for papers by Z Domljan Breakdown of academic impact, for papers by Pamela Bartels
Rankless by CCL
2026